Table 2. General and preoperative patient characteristics, including breakdown of composite comorbidity variables and preoperative laboratory chemistries.

Variable	Overall (<i>n</i> =77902)	No NRT (<i>n</i> =77561)	NRT (<i>n</i> =341)	P-value
General variables, mean			-	
±SD				
Age, years	58.6 ± 13.4	58.6 ± 13.4	57.4 ± 13.1	0.105
Body Mass Index, kg/m ²	28.5 ± 7.1	28.5 ± 7.1	28.5 ± 6.7	0.978
$WRVU^a$	13.4 ± 4.0	13.4 ± 4.0	15.1 ± 3.7	< 0.001
	125.7			
Operation time, min	± 102.6	125.6 ± 102.5	145.1 ± 122.9	0.002
Intraoperative transfusion ^b	0.0 ± 0.2	0.0 ± 0.2	0.1 ± 0.4	< 0.001
Other Variables, n (%)				
Chemotherapy in previous 30	3,696			
days	(4.7%)	3,593 (4.6%)	103 (30.2%)	< 0.001
Breast reconstruction				
technique				0.023
	11,552			
Tissue expanders	(68.5%)	11,510 (68.6%)	42 (56.0%)	
	2,335			
Implants	(13.8%)	2,324 (13.84%)	11 (14.7%)	
	2,976			
Autologous	(17.6%)	2,954 (17.6%)	22 (29.3%)	
Year of Operation, n (%)				0.066
	1,900	1,890	10	
2005	(2.4%)	(2.4%)	(2.9%)	
	6,600	6,579	21	
2006	(8.5%)	(8.5%)	(6.2%)	
	11,809	11,747	62	
2007	(15.2%)	(15.2%)	(18.2%)	
	13,684	13,621	63	
2008	(17.6%)	(17.6%)	(18.5%)	
	16,965	16,908	57	
2009	(21.8%)	(21.8%)	(16.7%)	
	17,209	17,135	74	
2010	(22.1%)	(22.1%)	(21.7%)	
2011	9,735	9,681	54	
2011	(12.5%)	(12.5%)	(15.8%)	
Race	- ·			0.907
	55,724			
White	(78.8%)	55,498 (78.8%)	226 (77.4%)	
	8,111			
African American	(11.5%)	8,073 (11.5%)	38 (13.0%)	
	3,609	. .		
Latino	(5.1%)	3,594 (5.1%)	15 (5.1%)	

	2,771			
Asian	(3.9%) 489	2,759 (3.9%)	12 (4.1%)	
American Indian	(0.7%) 71,404	488 (0.7%)	1 (0.3%)	
General anesthesia ASA class ^c	(91.7%)	71,080 (91.7%)	324 (95.0%)	0.446 <0.001
I	6,174 (7.9%) 48,571	6,161 (7.9%)	13 (3.8%)	
II	(62.4%) 22,092	48,393 (62.4%)	178 (52.2%)	
III	(28.4%) 915	21,947 (28.3%)	145 (42.5%)	
IV V	(1.2%)	910 (1.2%) 1 (0.0%)	5 (1.5%) 0 (0.0%)	
v Surgical wound class	1 (0.0%)	1 (0.0%)	0 (0.0%)	< 0.001
Surgical would class	75,910			<0.001
Clean	(97.4%) 1,555	75,591 (97.4%)	319 (93.5%)	
Clean-Contaminated	(2.0%) 260	1,542 (1.9%)	13 (3.8%)	
Contaminated	(0.3%) 177	254 (0.3%)	6 (1.7%)	
Dirty-Infected Functional status	(0.2%)	174 (0.2%)	3 (0.9%)	0.121
Independent	50,153 (98.5%) 651	49,948 (98.6%)	205 (97.2%)	
Partially dependent	(1.3%)	646 (1.3%)	5 (2.4%)	
Totally dependent	91 (0.2%) 10,734	90 (0.2%)	1 (0.5%)	
Smoking Inpatient status	(13.8%)	10,687 (13.8%)	47 (13.8%)	0.998 0.0089
Inpatient	35,374 (45.4%) 42528	35,195 (45.4%)	179 (52.5%)	
Outpatient Diabetic	(54.6%)	42366 (54.6%)	162 (47.5%)	0.516
	2,406			
On insulin	(3.1%) 5,723	2,392 (3.1%)	14 (4.1%)	
On oral drugs Alcohol intake in previous 2	(7.3%) 1,058	5,700 (7.4%)	23 (6.7%)	
weeks ^d	(1.4%)	1,047 (1.3%)	11 (3.2%)	0.003

Steroid use for chronic	1,076			
condition	(1.4%)	1,056 (1.4%)	20 (5.9%)	< 0.001
Pregnancy	92 (0.1%)	92 (0.1%)	0 (0.0%)	>0.999
Operation within previous 30	3,421	` ,	,	
days	(4.7%)	3,408 (4.7%)	13 (4.1%)	0.623
Cardiovascular Variables, n	` '	, , ,	,	
(%)				
Dyspnea				0.050
	240			
At rest	(0.3%)	237 (0.3%)	3 (0.9%)	
	5,245			
With moderate exertion	(6.7%)	5,215 (6.7%)	30 (8.8%)	
Congestive heart failure in	145			
previous 30 days	(0.2%)	144 (0.2%)	1 (0.3%)	0.471
	174			
Angina in previous 30 days	(0.2%)	174 (0.2%)	0 (0.0%)	>0.999
Myocardial infarction in				
previous 6 months	80 (0.1%)	80 (0.1%)	0 (0.0%)	>0.999
Previous percutaneous	1,636			
coronary intervention	(2.1%)	1,629 (2.1%)	7 (2.5%)	>0.999
	1,306			
Previous cardiac surgery	(1.7%)	1,301 (1.7%)	5 (1.5%)	>0.999
Hypertension requiring	32,054			
medication	(41.2%)	31,925 (41.2%)	129 (37.8%)	0.212
History of peripheral vascular	332			
disease	(0.4%)	329 (0.4%)	3 (0.9%)	0.179
Rest pain or gangrene	31 (0.0%)	31 (0.0%)	0 (0.0%)	>0.999
Composite cardiovascular				
morbidity not including HTN	3,353			
requiring medication	(4.3%)	3,336 (4.3%)	17 (5.0%)	0.534
Respiratory Variables, n				
(%)				
Current pneumonia	17 (0.0%)	17 (0.0%)	0 (0.0%)	>0.999
	1,967			
History of severe COPD	(2.5%)	1,952 (2.5%)	15 (4.4%)	0.027
Ventilator dependent in				
previous 48h	8 (0.0%)	8 (0.0%)	0 (0.0%)	>0.999
Composite respiratory	2,048			
morbidity	(2.6%)	2,031 (2.6%)	17 (5.0%)	0.006
Hepatobiliary variables, n				
(%)				
Ascites in 30 previous days	34 (0.0%)	34 (0.0%)	0 (0.0%)	>0.999
Esophageal varices in	• • • • • • • • • • • • • • • • • • • •	•0 (0 0+1)	0 (0 0 1)	0.000
previous 6 months	28 (0.0%)	28 (0.0%)	0 (0.0%)	>0.999
Composite hepatobiliary	50 (0 10)	50 (0.40()	0 (0 001)	0.000
morbidity	53 (0.1%)	53 (0.1%)	0 (0.0%)	>0.999

Renal variables, n (%)				
Renal failure	26 (0.0%) 200	26 (0.0%)	0 (0.0%)	>0.999
Presently on dialysis	(0.3%) 216	199 (0.3%)	1 (0.3%)	0.585
Composite renal morbidity	(0.3%)	215 (0.3%)	1 (0.3%)	0.613
Neurological variables, n (%)				
Impaired sensorium in				
previous 48h	31 (0.0%) 306	31 (0.0%)	0 (0.0%)	>0.999
Hemiplegia	(0.4%) 113	305 (0.4%)	1 (0.3%)	>0.999
Paraplegia	(0.2%)	113 (0.2%)	0 (0.0%)	>0.999
Quadraplegia	29 (0.0%)	29 (0.0%)	0 (0.0%)	>0.999
Coma lasting >24h History of transient ischemic	1 (0.0%) 1339	1 (0.0%)	0 (0.0%)	>0.999
attacks History of CVA ^e with	(1.7%) 865	1,334 (1.7%)	5 (1.5%)	>0.999
neurological deficit	(1.1%)	862 (1.1%)	3 (0.9%)	>0.999
History of CVA without	916			
neurological deficit	(1.2%)	912 (1.2%)	4 (1.2%)	>0.999
Tumor involving CNS	44 (0.1%)	40 (0.1%)	4 (1.2%)	< 0.001
Composite neurological	3,104	2.004 (4.004)	10 (0.00)	0.000
morbidity	(4.0%)	3,091 (4.0%)	13 (3.8%)	>0.999
Hematology-oncology				
variables, n (%)	1,309			
Bleeding disorder	(1.7%)	1,294 (1.7%)	15 (4.4%)	< 0.001
Weight loss >10% in previous	364	1,201 (1.770)	13 (1.170)	<0.001
6 months	(0.5%)	356 (0.5%)	8 (2.4%)	< 0.001
	1,043	,	,	
Disseminated cancer	(1.3%)	992 (1.3%)	51 (15.0%)	< 0.0001
Composite hematology-	2,625			
oncology variable	(3.4%)	2,555 (3.3%)	70 (20.5%)	< 0.001
Preoperative laboratory				
studies, n (%)	2.121			
0 1 12 125 1/1	3,131	2 100 (5 40/)	22 (0.20()	0.041
Serum sodium ≤135 mmol/L	(5.4%) 622	3,108 (5.4%)	23 (8.2%)	0.041
Serum sodium >145 mmol/L	(1.1%)	620 (1.1%)	2 (0.7%)	0.774
Blood urea nitrogen >143	29,016	20.000 (40.000)	100 (47 00)	0.12.52
mmol/L	(49.7%)	28,888 (49.8%)	128 (45.2%)	0.1363
Serum creatinine >16·1 μmol/L	2,207 (3.7%)	2,201 (3.7%)	6 (2.1%)	0.158
μποι/L	(3.770)	2,201 (3.770)	0 (2.170)	0.136

	3,112			
Total bilirubin >1.9 mg/dL	(7.2%)	3,102 (7.2%)	10 (4.7%)	0.155
Aspartate aminotransferase >4	2,547			
U/L	(5.7%)	2,525 (5.7%)	22 (10.0%)	0.012
Alkaline phosphatase >125	2,441			
U/L	(5.4%)	2,413 (5.4%)	28 (13.0%)	< 0.0001
White-blood-cell count >11,	2,854			
cells per μl	(4.5%)	2,845 (4.5%)	9 (3.0%)	0.215
	1,874			
Platelet count ≤15, cells per μl	(3.0%)	1,855 (3.0%)	19 (6.4%)	< 0.001
International normalized ratio	564			
>1.4	(3.2%)	562 (3.2%)	2 (2.0%)	0.773

^aWork relative value unit is a scale (0−95) to quantify the amount of work involved in a specific surgery on the basis of pre-procedural, intra-procedural, and post-procedural time, technical skill, physical effort, mental effort and judgment, and stress due to potential risk; the scale is the work portion of the Resource-based Relative Value System adopted by US Medicare to quantify the amount of work involved in every medical procedure (score of 0=least complex and 95=most complex). ^bTransfusion of any number of units intraoperatively for all years. ^cASA= American Society of Anesthesiologists. ASA scores: I is a healthy patient; II is mild systemic disease but no functional limitations; III is severe systemic disease with definite functional limitations; IV is severe systemic disease that is a constant threat to life; and V is a moribund patient unlikely to survive 24 h with or without an operation. ^d>2 drinks per day. ^eCVA = cerebrovascular accident.